Navigation Links
Hepatitis C drug can cause depression
Date:5/1/2012

MAYWOOD, Ill. -- There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

In a review article, researchers tackle the complexities of diagnosing and managing depression before and after initiating treatment with interferon.

Dr. Murali S. Rao of Loyola University Medical Center is a co-author of the study, published in the International Journal of Interferon, Cytokine and Mediator Research.

"Depression is a relatively frequent and potentially serious complication of interferon therapy for hepatitis C virus infection," the researchers write. "However, other etiologies [causes] of depression may coexist and have to be carefully excluded."

Hepatitis C is the most common chronic blood-borne infection in the United States. At least 4 million people have been exposed and 3.2 million are chronic carriers.

The drugs ribavirin and pegylated interferon are mainstay treatments. Pegylated interferon can help relieve muscle and joint pain and reduce the disabling fatigue. But a well-established side effect of interferon is depression of variable severity -- including suicidal thoughts. The prevalence of depression among hepatitis C patients receiving interferon has been reported to be between 10 percent and 40 percent, depending on the screening method used.

One of the main concerns in treating hepatitis C patients is the risk of suicide, especially since many patients already are depressed before beginning therapy. Patients who have a personal or family history of a serious mood disorder, depression, suicidal thoughts or suicide attempts "should be carefully interviewed and referred to a specialist for assessment of suicide risk and treatment of the underlying disorder before treatment with interferon can be considered," the authors write.

The SSRI class of antidepressants, such as citalopram (brand name, Celexa), have been shown to be effective in treating depression in hepatitis patients treated with interferon. The related SNRI class of antidepressants, such as milnacipran (Savella), also can reduce depressive symptoms in patients taking interferon. But there have been conflicting results in studies on whether giving antidepressants before starting interferon can prevent depression, the authors write.

Interferon can affect the level of serotonin, a compound that is responsible in part for regulating mood and other brain functions. This may be the reason why antidepressants don't always work in patients who take interferon, the authors write.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Over 20 million individuals infected with hepatitis E in Asia and Africa
3. Broader screening for hepatitis C would be cost effective, study suggests
4. Hepatitis C Now Kills More Americans Than HIV
5. MIT: Stem cells could drive hepatitis research forward
6. Stem Cells May Further Hepatitis C Research
7. Statins May Stave Off Liver Cancer in People With Hepatitis B
8. Many U.S. Adults Not Vaccinated for Hepatitis B
9. New Drug Combo for Hepatitis C Shows Promise
10. UBC researchers identify potential new therapy approach for hepatitis C
11. New fibrosis classification improves accuracy of diagnosis in hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... Falls Church, VA (PRWEB) , ... September 21, ... ... Use Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the ... every edge they can get while staying in compliance with FDA rules. , ...
(Date:9/21/2017)... WA (PRWEB) , ... September 21, 2017 , ... ... technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in ... of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that ... detail to the athletic wear market with the launch of their FlipBelt Crops. , ... their essentials securely at their fingertips while at the gym, on the trail, or ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), combines ... Artificial Intelligence (AI) thinking, announced today the launch of its revamped web presence. ... information that offers a more comprehensive understanding of the organization’s business and machine ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology: